Publisher
Computers, Materials and Continua (Tech Science Press)
Reference13 articles.
1. Aapro M, Leonard RC, Barnadas A (2008) Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracyclineand/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) Study. J Clin Oncol 26: 592–598
2. Aapro MS, Bohlius J, Cameron DA, et al (2010) Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced fébrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer
3. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13: 33–36
4. Bouchet JL, Brunet P, Canaud B, et al (2009) Recommandations d’utilisation des biosimilaires de l’érythropoïétine (EPO). Nephrol Ther 5: 61–66
5. Brockemeyer C, Seidl A (2009) Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHPP 15: 34–40